Literature DB >> 28098855

Regulation of EMT by STAT3 in gastrointestinal cancer (Review).

Bo Li1, Chen Huang1.   

Abstract

Gastrointestinal (GI) cancer is characterized by its aggressiveness and tendency to metastasize at early stage. Epithelial-mesenchymal transition (EMT), commonly known as the preparing step of metastasis, may account for the aggressive phenotype of GI cancer cells. The process of EMT is finely orchestrated by multiple layers of regulators. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor constitutively activated in diverse malignancies. Recent studies have suggested an involvement of STAT3 in GI cancer EMT. In this review, we first take an insight into the oncogenic functions of STAT3 in GI cancer, and then summarize the possible mechanisms by which STAT3 regulates the EMT process. Through the extensive interactions with EMT-inducing transcription factors and non-coding RNAs, and crosstalk with other signaling pathways, STAT3 has been demonstrated to promote the mesenchymal and invasive phenotype of GI cancer, which provides rationales for specifically targeting STAT3 to prevent and reverse the progression of GI cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28098855     DOI: 10.3892/ijo.2017.3846

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  28 in total

1.  AGEs induce epithelial to mesenchymal transformation of human peritoneal mesothelial cells via upregulation of STAT3.

Authors:  Pei Zhang; Hong Dai; Lei Peng
Journal:  Glycoconj J       Date:  2019-02-28       Impact factor: 2.916

2.  Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling.

Authors:  Wei Liu; Xindi Wang; Le Wang; Yu Mei; Yanning Yun; Xiaobao Yao; Qian Chen; Jinsong Zhou; Bo Kou
Journal:  Int J Med Sci       Date:  2022-05-27       Impact factor: 3.642

Review 3.  Epithelial-to-mesenchymal transition in tumor progression.

Authors:  Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2017-05-30       Impact factor: 3.064

Review 4.  The potential role of leptin in tumor invasion and metastasis.

Authors:  Amitabha Ray; Margot P Cleary
Journal:  Cytokine Growth Factor Rev       Date:  2017-11-11       Impact factor: 7.638

5.  Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells.

Authors:  Mei Xiang; Zihong Chen; Donghong Yang; Haiwen Li; Yufang Zuo; Jingjing Li; Wendian Zhang; Hechao Zhou; Danxian Jiang; Zumin Xu; Zhonghua Yu
Journal:  Oncol Lett       Date:  2017-06-12       Impact factor: 2.967

6.  Overexpression of serine protease HtrA enhances disruption of adherens junctions, paracellular transmigration and type IV secretion of CagA by Helicobacter pylori.

Authors:  Aileen Harrer; Manja Boehm; Steffen Backert; Nicole Tegtmeyer
Journal:  Gut Pathog       Date:  2017-07-25       Impact factor: 4.181

7.  Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.

Authors:  Yushan Yang; Lulu Ma; Yiming Xu; Yun Liu; Wenya Li; Jianchun Cai; Yiyao Zhang
Journal:  Cell Death Dis       Date:  2020-06-24       Impact factor: 8.469

8.  Rab18 Regulates Proliferation, Invasion and Cisplatin Sensitivity Through STAT3 Signaling in Head and Neck Squamous Cell Carcinoma.

Authors:  Xu Ji; Xing Guo; Yan Wang; Xiaotian Li; Hong Li
Journal:  Onco Targets Ther       Date:  2020-05-13       Impact factor: 4.147

9.  Aberrant Non-Coding RNA Expressed in Gastric Cancer and Its Diagnostic Value.

Authors:  Zhilong Yu; ZeYin Rong; Jinxin Sheng; Zai Luo; Jianming Zhang; Tengfei Li; Zhonglin Zhu; Zhongmao Fu; Zhengjun Qiu; Chen Huang
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

Review 10.  Chemotherapy: a double-edged sword in cancer treatment.

Authors:  Nafiseh Behranvand; Farzad Nasri; Reza Zolfaghari Emameh; Pouria Khani; Asieh Hosseini; Johan Garssen; Reza Falak
Journal:  Cancer Immunol Immunother       Date:  2021-08-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.